The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
 
Nicholas Turner
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Yeon Hee Park
Honoraria - AstraZeneca; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Inocras (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Gilad
 
Wolfgang Janni
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; Seagen
Research Funding - Amgen (Inst); Janssen Diagnostics; Lilly (Inst); Menarini Silicon Biosystems; NeoGenomics Laboratories (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; Novartis; Pfizer; Roche
 
Cynthia Ma
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Danatlas; Foundation Medicine; Genzyme; Lilly; Merck; Merck; Novartis; Olaris; Pfizer; Regor Therapeutics Group; Stemline Therapeutics; Stemline Therapeutics; Tersera; Tersera
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.
 
Massimo Cristofanilli
No Relationships to Disclose
 
Giampaolo Bianchini
Honoraria - AstraZeneca/Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Kevin Kalinsky
Employment - EQRx (I)
Stock and Other Ownership Interests - EQRx (I)
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; mersana; Mersana; Myovant Sciences; Novartis; Pfizer; Prelude Therapeutics; ProteinQure; Puma Biotechnology; RayzeBio; Regor; Relay Therapeutics; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Stephen Chia
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Peter Fasching
Honoraria - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Guardant Health; Hexal; Lilly; Menarini Group; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Pfizer (Inst); Roche
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Zbigniew Nowecki
No Relationships to Disclose
 
Javier Pascual
Honoraria - AstraZeneca; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly; Menarini; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer
 
Lionel Moreau
No Relationships to Disclose
 
Shin-Cheh Chen
No Relationships to Disclose
 
Sasha McClain
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - AstraZeneca (I)
 
Steven Fox
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca
 
Cynthia Bartlett
Employment - AstraZeneca; Merck; Pfizer
Stock and Other Ownership Interests - AstraZeneca; Pfizer
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Foresight Diagnostics; Inatherys; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; SAGA Diagnostics
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Roche
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); Roche (Inst); SAGA Diagnostics (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst); Prognosis assessment by a digital pathology assay in early breast cancer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche